Compare OMCL & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMCL | NNNN |
|---|---|---|
| Founded | 1992 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2000 | N/A |
| Metric | OMCL | NNNN |
|---|---|---|
| Price | $34.96 | $24.10 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $53.67 | N/A |
| AVG Volume (30 Days) | ★ 517.9K | 28.9K |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $787,309,000.00 | N/A |
| Revenue This Year | $6.77 | N/A |
| Revenue Next Year | $5.22 | N/A |
| P/E Ratio | $857.75 | ★ $446.57 |
| Revenue Growth | ★ 9.93 | N/A |
| 52 Week Low | $22.66 | $5.91 |
| 52 Week High | $51.84 | $55.65 |
| Indicator | OMCL | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 37.86 | 52.91 |
| Support Level | $33.25 | $19.53 |
| Resistance Level | $37.51 | $30.70 |
| Average True Range (ATR) | 1.33 | 1.96 |
| MACD | -0.09 | 0.40 |
| Stochastic Oscillator | 26.83 | 88.63 |
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.